[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.189.139. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
June 9, 2004

Soluble RANKL and Risk of Nontraumatic Fracture

Author Affiliations
 

Letters Section Editor: Stephen J. Lurie, MD, PhD, Senior Editor.

JAMA. 2004;291(22):2703. doi:10.1001/jama.291.22.2703-a

To the Editor: Dr Schett and colleagues1 reported that a low level of the receptor activator of nuclear factor κB ligand (RANKL) is an independent predictor of nontraumatic fracture and that it may gain relevance for assessment of fracture risk. However, the study has several weaknesses, and important information is missing.

First, the study is based on what appears to be an untested laboratory method. Soluble RANKL levels in normal serum are extremely low, in the (sub)picomolar range. According to Schett et al, RANKL was measured "by a commercial sandwich enzyme-linked immunosorbent assay [ELISA] (Biomedica, Vienna, Austria) as described [in their reference 12]." In contrast with Biomedica's OPG ELISA, I have not been able to find any references to publications using this product or showing validity and reliability on Biomedica's Web site, and it is not mentioned in the article's reference 12, which describes immunoprecipitation of murine RANKL. In addition, it is not clear in the "Laboratory Methods" section whether each participant's serum was analyzed as a single sample, in duplicate, or in triplicate. Although the levels are reported to be stable over time, the correlation between 1990 (or 1995) and 2000 measurements is not shown, and the regression line in Figure 2 in the article seems to be based on the few individuals with RANKL concentrations greater than 2 pmol/L.

First Page Preview View Large
First page PDF preview
First page PDF preview
×